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THE LOWDOWN ON  
OUT-OF-COMPETITION  
TESTING
WHAT THE RMTC ISN’T TELLING US ABOUT ITS PROPOSED REGULATIONS
By Clara Fenger, DVM, PhD, DACVIM; Tanya Boulmetis, JD; Kim Brewer, DVM; and Thomas Tobin, MRCVS, Phd, DABT; Photos by Denis Blake
FEATURE
he corner office has a beautiful view, with filtered sunlight shining 
through full plate glass. Grand old oak trees provide shade for much 
of the year to the building that houses the registry of the American 
Thoroughbred. Professionals. Many years of experience populate 
the offices, far from the distinctive scent and dust of the racetrack. Among 
those distinguished leaders are men who began their careers working up from 
the mailroom of a racetrack or from the stables of an Arabian horse farm. 
Many years and miles removed from the actual day-to-day work of sending 
out a Thoroughbred for a morning workout, mucking stalls or rubbing down 
the athlete at the end of the morning, these executives propose to reform 
medication rules. Their latest initiative to this end is support of an out-of-
competition testing regulation promulgated by the Racing Medication and 
Testing Consortium (RMTC), an organization housed under the same roof, 
shaded by the same oak trees.
Horse racing is both the Sport of Kings and an economic engine for people 
across all spectra of socioeconomic status. The reliance on wagering to sustain 
the sport leads many to suspect that anyone who wins at a high percentage 
must be using “something” to gain an unfair advantage over his or her 
T
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competitors. The perceived potential for such activities has led to a unique and 
early history of drug testing advances in horse racing, with methods that long 
predate drug testing in any human sport. This attention to the integrity of the 
sport has paid off for modern-day horse racing, with fewer than 0.5 percent of 
all post-race tests returning a positive, and most of those are trace overages of 
therapeutic medications that would be legal, indeed at times not even tested 
for, in any human sport. This low violation rate is less than half of the number 
of violations reported in human sports, and it does not include the widespread 
practice of approved therapeutic use exemptions in human drug testing, 
in which otherwise prohibited drugs are permitted during competition for 
therapeutic use. The only area in which human testing has surpassed equine 
testing is in its common use of out-of-competition testing.
ERYTHROPOIETIN
Out-of-competition testing is important because some substances 
can exert an effect on an athlete long after the substance can no longer be 
detected in the typical post-race drug-testing sample. The poster-child drug 
for which out-of-competition testing is required is erythropoietin (EPO) and its 
analogues. EPO is a hormone produced by the kidneys in response to a reduced 
oxygen environment; it travels from the kidneys to the bone marrow, where it 
stimulates the production of red blood cells. This hormone is naturally present 
all the time in all horses, and the balance of EPO, iron and key vitamins folate 
and B12 combine to maintain a steady level of red blood cell production by the 
bone marrow.
This balance is important in maintaining the delivery of oxygen to 
exercising muscles—a key determinant of optimal racing performance. Horses 
are unique among athletes in that their blood moves with such great speed 
throughout their bodies and across their lungs during maximal effort that 
the blood cannot be fully saturated with oxygen as it traverses the pulmonary 
circulation. This exercise-associated hypoxemia is not observed in other 
species and likely contributes to the possibility of improvement in performance 
following EPO administration in horses. If you can increase the oxygen-carrying 
capacity of the blood, you can deliver more oxygen to the muscles. 
What makes EPO a hormone of great threat to the integrity of any sport 
is that small doses administered at regular intervals will stimulate the 
production of red blood cells, cells that persist in the bloodstream for months 
and far outlast the two- to three-day presence of detectable amounts of the 
EPO hormone in blood. In this way, any performance-enhancing effect of EPO 
would long outlive the ability of any testing laboratory to actually detect the 
offending EPO.
OUT-OF-COMPETITION 
TESTING 
In 2007 the Association of Racing Commissioners International (RCI) 
adopted an out-of-competition testing regulation, which, for the first time, 
instituted a policy for the collection of blood samples for the detection of 
EPO outside of the post-race testing situation. This regulation represented 
a significant advance in the ability of racing commissions to address the 
problem of EPO misuse in horse racing. Since that time, out-of-competition 
testing has steadily increased, with a high of 3,805 such tests in 2015, of 
which 45 returned a laboratory finding (a 1.2 percent positive rate). None of 
those positives actually represented an illegal finding. Cobalt was responsible 
for 44 of those findings, which did not even represent an illegal finding at 
the time of the testing and could have resulted from the sampling of a horse 
shortly after an innocent administration of vitamin B12. The remaining finding 
was for the dewormer levamisole, a substance of invaluable use in horses as 
an immune modulator for such diseases as equine protozoal myelitis or Lyme 
disease. So the 1.2 percent positive rate from 2015 represented not a single 
real violation. Either racing is doing a great job in controlling illicit substance 
administrations or we are not testing a sufficient number of horses.
In a recent statement published in Thoroughbred Daily News, The Jockey 
Club President and COO Jim Gagliano challenged the racing industry to adopt 
the RMTC’s far-reaching out-of-competition testing proposal to ensure “the 
integrity of competition.” 
Surely, if out-of-competition testing could be expanded, we as an industry 
could confidently proclaim that all is being done to ensure the integrity of horse 
The Jockey Club-supported RMTC regulation would ban some 
theraputic medications at any time during the competition life  
of the horse—on the backside of a racetrack, on farms, even  
at layup facilities in states in which no racing is held.
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racing. As outlined above, EPO poses a substantial threat to the integrity of 
horse racing, and every stakeholder in the industry should stand firmly behind 
the expansion of out-of-competition testing. Or should they? First, let’s look 
carefully at the actual RMTC proposal. 
THE RMTC PROPOSAL
The RMTC’s proposal would expand out-of-competition testing well 
beyond EPO and related agents and directly into routine practice of veterinary 
medicine. First, it bans all non-FDA-approved substances, an apparently 
noble goal on its surface; after all, drug companies have expended millions 
to demonstrate that their FDA-approved drugs are safe and effective, and our 
industry should be in support of making sure that our athletes receive only 
the highest-quality medicines. The first exception is that our federal and state 
governments have made numerous provisions for the use of medications that 
were in widespread use at the time that the current system of FDA approval 
was introduced, as well as for the use of compounded medications, which are 
legal when there is no FDA-approved alternative available. Strict restrictions 
are already in place for the control of such substances in post-race testing, but 
The Jockey Club-supported RMTC regulation would ban them at any time during 
the competition life of the horse—on the backside of a racetrack, on farms, 
even at layup facilities in states in which no racing is held. Aside from the 
negative impact on the athlete itself, when treatment options for any number 
of conditions would be limited, trainers and owners could be held liable for the 
actions of any manager or veterinarian, unlicensed by any commission, acting 
innocently and in good faith in the best interests of the health and welfare of 
the horse.
The list of prohibited substances appears to have been slightly modified 
from the list that appears on the World Anti-Doping Agency website  
(wada-ama.org/en/what-we-do/prohibited-list) and includes cytokines and 
growth factors, which are specifically used in regenerative medicine, such as 
Interleukin-1 Receptor Antagonist Protein and platelet-rich plasma, for which, 
incidentally, no detection technology, out-of-competition testing or otherwise, 
currently exists. In human sports, such methods of promoting better and faster 
healing from sports injuries are considered illegal, taking an unfair advantage 
over competitors. This concept of “cheating” is inappropriate in equine sports, 
where failing to allow a horse to recuperate to its fullest extent could both 
predispose the horse and its rider to catastrophic injury and prevent the 
equine athlete from having a successful second career after racing. The use 
of such growth factors as targeted therapies for joints, tendons and ligaments 
should be encouraged in our athletes rather than added to a long list of 
prohibited substances.
Thyroxine, adrenocorticotropin and human chorionic gonadotropin, 
substances in common use for the purpose of treating specific conditions 
in horses, are included on the RMTC’s proposed rule. The RMTC provides no 
evidence that the use of any of these substances poses a risk to the integrity 
of racing. These substances are currently prescribed pursuant to a specific 
diagnosis in horses both on and off the track on a daily basis. This regulation 
seeks to permit the use of thyroxine only after permission is given by the 
regulatory authority. So if your vet pulls a blood test and determines that 
the horse has a low level of thyroxine, you cannot supplement the horse until 
permission is received by the regulatory authority. The RMTC’s regulation would 
put bureaucrats in the place of your own veterinarian in making health and 
welfare decisions for your horse. 
There are many issues with this scenario of regulatory permission 
being required to use a legal medication during training or recuperation. For 
example, say the state that you requested permission from refuses to allow 
the medication. After the refusal, you ship to another state, again request 
permission, have it granted and medicate your horse. Then the state that 
refused permission tests your horse out of competition. Obviously, it would 
be positive. Who is liable? State budgets are constrained enough without 
looking for lawsuits. Another issue would be the timeframe between requesting 
permission and receiving it. It would put the commission in the untenable 
position of being able to refuse or delay approval in order to tacitly punish a 
horseman who, without any proof, they “felt” was cheating. 
Anabolic steroids would be further restricted in this out-of-competition 
testing regulation well beyond their current restrictions within proximity 
to racing. Horses are unique among athletes in that we geld our athletes, 
for which there is no corollary in human sports. Anabolic steroids may be 
required for normal recovery from injury and disease, and like growth factors, 
any intervention we can provide to horses that may lead to a fuller and more 
rapid recovery should be encouraged. Any human bodybuilder or weight lifter 
can attest that using cycles of anabolic steroids will enhance performance, 
but the existing minimum withdrawal of 60 days from racing prevents such 
abuse. This regulation would require placing the horse on the vet’s list for six 
months, which is lightyears in horse racing, and would effectively ban the use 
of these substances at any time in a racing horse. Further, stanozolol, the only 
FDA-approved anabolic steroid that provides the benefits of anabolic steroids 
without the disadvantage of causing studdish behavior, would be banned at 
all times. This regulation would prevent the beneficial use of anabolic steroids 
based solely on the premise that it looks good to the public.
THERAPEUTIC SUBSTANCES
In addition to the restrictions on specific widely used therapeutic 
substances, an even more sinister provision is hidden within this proposed 
regulation. A provision calls for out-of-competition testing to be used to police 
other racing regulations not contained within the language of the out-of-
competition testing regulation. On the surface, this sounds innocuous enough, 
but a careful review reveals the following possible intent in the regulation. If a 
horse tests positive for a therapeutic substance—for example, methocarbamol 
or dexamethasone—and there is no vet record or prescription for that 
substance for that horse, a violation has occurred. In the current environment 
of picogram identifications at the laboratory, where most methocarbamol and 
dexamethasone identifications are the result of inadvertent environmental 
contamination, trainers will be penalized for trace medication levels over which 
they have no control.
A further issue with this scenario would be for a medication of which 
trace levels may be found for an extended period of time after the last 
administration. For example, horses in training can be purchased at auction, 
leading to the question of who is liable when a horse that recently has been 
purchased tests positive and only has been in its new barn for a few weeks. 
New York takes this into account and has a provision through which the new 
owner may void the purchase within 10 days of notification. However, what if 
the sale was months ago? The conditions of sale for both Keeneland and Fasig-
Tipton do not take a position through which a horse may be returned months 
later. Again, this could be an expensive litigation scenario for both states and 
horsemen. There is even a provision in the proposed RMTC regulation for hair 
testing, in which substances could be found for up to a year later, and other 
biologic samples as yet undefined.
EXISTING REGULATIONS
A racing commission that is considering adopting the RMTC’s 
recommendation should carefully evaluate the validity of the out-of-competition 
testing rules; they need to consider whether it falls within the scope of the 
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What happens if trace levels of a substance administered before 
a 2-year-old or horses of racing age sale are found months later 
after the horse has changed hands?
jurisdiction conferred by their legislature. Each state has its own enabling 
statute concerning horse racing. In general, the proposed rule must have a 
rational and reasonable basis and be based on objective science. It must 
safeguard the constitutional rights and ensure fairness to all horsemen. In 
2006 Ontario was the first jurisdiction to launch an out-of-competition testing 
program, and many jurisdictions followed suit. These adopted rules range from 
the very narrow, in which there are defined parameters of which horses are 
eligible and what is tested for, to extremely broad, in which a state could make 
a case to test the majority of the horse population in the United States—even 
if that horse had never been in that specific state. 
Some states test only for the blood doping substances and limit the 
eligible horses to jurisdiction grounds or to horses that are racing in the 
state. Some test only blood, and others allow urine and hair testing. Other 
states, however, are testing for a very broad range of substances, some 
of which include drugs that can be a result of inadvertent environmental 
contaminations, such as zilpaterol and ractopamine. 
Delaware falls into the narrow out-of-competition testing rule category. 
The state tests for blood doping on any entered horse, any horse that raced 
there within the past 60 days, any horse that showed the presence of blood 
doping antibodies at some point, a horse with a trainer who has ever had 
a horse test positive for EPO and any horse that dies or is euthanized on 
association grounds for any reason. 
Kentucky falls into the latter category; “any horse eligible to race in 
Kentucky” is its guideline. Kentucky defines this as a horse being eligible if 
the owner or trainer is licensed in that state, if it is nominated to a race in 
that state or if it raced in Kentucky within the past 12 months, if it is stabled 
at a racetrack or licensed training facility or if it is nominated to the Kentucky 
Thoroughbred Development Fund. Kentucky testing is supposed to be limited 
to natural or synthetic types of blood doping substances, venoms and growth 
hormones. 
New Mexico is broader in what it tests for but slightly limited more to 
horses in its area. The state may test horses on the grounds, horses with 
papers that are on file, horses nominated to stakes or horses with an owner or 
trainer licensed in the state. New Mexico also tests for clenbuterol and anabolic 
steroids in addition to the Kentucky list. It also may test urine and hair, in 
addition to blood. Illinois tests for blood and gene doping but specifically added 
the following wording: “This Section does not apply to therapeutic medications 
approved by the FDA for use in the horse.” 
Gagliano, in his statement to the Thoroughbred Daily News, bemoaned the 
fact that only 19 out of 38 states have out-of-competition testing. Perhaps the 
states that are not currently doing this testing are waiting for a good rule to 
follow. Racing commissions are woefully underfunded. Adopting a specific rule 
just because it has the RMTC’s blessing does not mean it will stand up in a 
court challenge. New York had an expensive, protracted legal fight on this issue, 
the outcome being that the lawsuit was dropped when New York amended its 
rule. The states that wait may be better off; they can create a fair and legally 
validated rule, one that targets the cheaters and only the cheaters, and a rule 
that will stand up when challenged in court. 
All these states have a noble idea—get rid of the cheaters in the industry 
and make it an even playing field for all horsemen. However, in the RMTC’s 
quest to make the public think they are getting “tough on racing,” they actually 
may be diluting the effectiveness of out-of-competition testing. 
As it stands, California has the highest percentage of out-of-competition 
testing, at 10 percent of all drug testing. Contrast this to Kentucky, where 
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Immediately following the Global Symposium on Racing and Gaming 
in Tucson, Arizona, the Association of Racing Commissioners International 
(RCI) scheduled meetings on December 8 and 9 at the Omni Resort, also in 
Tucson. The National HBPA was present and represented by Dave Basler, 
executive director of the Ohio HBPA, along with National HBPA President 
and Chair Leroy Gessmann and CEO Eric Hamelback. The RCI Model Rules 
Committee met first, followed by the RCI Board of Directors.
The RCI Model Rules Committee convened to discuss several topics. 
One of those was the proposed changes submitted by the Racing Medication 
and Testing Consortium (RMTC) to the current Multiple Medication Violation 
(MMV) phase of the National Uniform Medication Program (NUMP). 
Significant work went into reevaluating the current MMV phase by a 
subcommittee of the RMTC, which was composed of a wide array of industry 
stakeholders. Following the subcommittee’s changes and recommendations, 
the RMTC board approved the amendments, which were then proposed in 
writing to the RCI with the intention to amend the current model rule.
The changes that were amended to the MMV allowed for decreases 
in the amount of time that points remain on a trainer’s record as well 
as a decrease in the number of points assigned for medications that are 
not performance-enhancing. More importantly, the changes would allow 
stewards to have discretion in how many—if any—points are awarded 
in cases where a positive test is the result of contamination and proven 
through mitigating circumstances.
The significant progress made to improve the MMV component of the 
NUMP now allows for support given to this phase by the NHBPA.
The changes were supported by a wide range of industry participants, 
including the NHBPA and RMTC. The only opponent of the changes was The 
Jockey Club.
“With the sensitivity of today’s testing, trainers are at a constant risk 
of having a positive test from a miniscule amount of a substance a horse 
might have ingested through contaminated feed, hay or other environmental 
factors or through human contact,” said Hamelback. “Furthermore, these 
positives are sometimes called at levels and for medications that could not 
possibly affect performance on the track, so this is certainly a step in the 
right direction. We thank the RCI, RMTC and all the other industry groups 
who came together to improve the MMV and make it a fair system for all.”
Another topic discussed by the RCI Model Rules committee was the 
proposed model rule discussed in this article to allow for out-of-competition 
testing. While the NHBPA has been on the record supporting out-of-
competition testing, it was important to note horsemen’s concerns related to 
the drafted proposed model rule. The intention of the NHBPA’s presence at 
the meeting was to state the organization’s opposition to the current content 
and to express apprehension regarding the overreaching intent, which would 
cause concern for horsemen’s rights.
Working together with Alan Foreman of the Thoroughbred Horsemen’s 
Association, the NHBPA was successful in presenting opposition to the 
original proposed model rule and thus initiating significant changes. While 
concerns can still be voiced, the changes initiated by the Model Rules 
Committee were very much in the favor of horsemen’s rights. Of particular 
importance was the change made to the new out-of-competition testing 
draft going before the RCI full board that involved the exclusion of results 
found regarding therapeutic medications as non-relevant findings.
The NHBPA believes the progress made in the past few months has 
been very encouraging. While it is important to say that we are working 
together with many other stakeholders to initiate uniformity, it is also very 
important to note that the voices and concerns identified for many years by 
the NHBPA are finally getting proper recognition and orchestrating positive 
change for our industry.
a generous estimate is 2 percent of all drug testing. The RMTC regulation 
heralded by Gagliano expands out-of-competition testing to routine therapeutic 
medications, rather than expanding the number of horses tested for EPO 
analogues or providing funding to develop testing for designer drugs. In 
support of its regulation, the RCI recently sent out a survey that asked whether 
respondents were in favor of expanded testing. What RCI failed to define was 
“expanded.” Rather than expanding testing for substances that might actually 
damage the integrity of horse racing, the proposed regulation seeks to expand 
out-of-competition testing to legitimate therapeutic medications. By expanding 
this testing to legitimate therapeutic medications, the proposed rule gives 
chemists something to report in their out-of-competition testing reports and 
thereby justifies the out-of-competition testing process and the entire regulatory 
process itself and as such points to the claimed efficacy of the rule. Financially, 
this approach has only one result. There will be fewer horses tested.
During the 2013 University of Arizona Global Symposium on Racing and 
Gaming, Alan Foreman, chair of the Thoroughbred Horsemen’s Association, said 
out-of-competition testing is designed to detect the use of substances like 
blood-doping agents and “emerging drugs” like peptide venoms that can have 
pain-killing effects. Testing for these illicit substances is “more important than 
testing for 24 therapeutic drugs. Those aren’t the drugs compromising racing.”
CONCLUSION
As Gagliano suggests, the expansion of out-of-competition testing is a 
goal worthy of widespread industry support. However, the details of the current 
RMTC proposal, supported by The Jockey Club, fall short of actually improving 
the integrity of horse racing. There are currently more than 80 EPO analogues, 
and technology is only capable of identifying a handful. Designer anabolic 
steroids and peptides can only be detected in limited numbers, because the 
technology for finding anything is only now being developed. There is a need 
for expanded out-of-competition testing and more widespread adoption of the 
current regulations by racing jurisdictions but not for expanding this testing 
into the administration of legitimate therapeutic medications. The proposed 
regulation only criminalizes legal activity without providing even the tiniest 
of steps toward addressing the true threats to the integrity of horse racing. In 
the meantime, horsemen and vets have to waste precious resources and time 
fighting the implementation of overly broadly drafted rules when our efforts, 
one and all, would be better spent focusing as a united industry on ways to 
identify true cheating. The mission of The Jockey Club would be better served 
if its executives would emerge from their offices in the shade of the oak trees 
and walk the backsides of our racetracks talking to the actual people who keep 
them in their jobs.
UPDATE: NATIONAL HBPA WORKING HARD FOR POSITIVE CHANGE
